<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Verena</forename><surname>Tscholl</surname></persName>
							<email>verena.tscholl@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><surname>Abdullah</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Khaled-A</forename><surname>Lsharaf</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tina</forename><surname>Lin</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Cardiology and Electrophysiology</orgName>
								<orgName type="institution">HeartCare</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<region>Victoria</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Bellmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">Patrick</forename><surname>Nagel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klaus</forename><surname>Lenz</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute for Biometry and Clinical Epidemiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Landmesser</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mattias</forename><surname>Roser</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Rillig</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">Benjamin Franklin Campus</orgName>
								<address>
									<addrLine>Hindenburgdamm 30</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">A29BA965D5A12C7F381514B9137DCFB4</idno>
					<idno type="DOI">10.1002/clc.22782</idno>
					<note type="submission">Received: 5 June 2017 Revised: 22 July 2017 Accepted: 28 July 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Bleeding</term>
					<term>Catheter Ablation</term>
					<term>Cryoballoon Ablation</term>
					<term>Novel Oral Anticoagulants</term>
					<term>Phenprocoumon</term>
					<term>Safety</term>
					<term>Stroke</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Data are limited on the safety of periprocedural anticoagulation with novel oral anticoagulants (NOACs) in patients undergoing pulmonary vein isolation (PVI) using the second-generation cryoballoon (CB) for the treatment of atrial fibrillation.</s></p><p><s>Hypothesis: We hypothesized that the incidence of acute periprocedural complications in patients undergoing PVI do not differ between patients treated with VKA compared to NOACs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods:</head><p><s>In 200 consecutive patients (mean age, 64.3 _ 10.6 years; female, n = 83) with symptomatic atrial fibrillation, PVI using the second-generation 28-mm CB was performed.</s><s>In patients treated with NOACs, the medication was stopped the day of the procedure and continued the evening after the procedure with a reduced dosage.</s><s>Patients treated with phenprocoumon were continued on uninterrupted phenprocoumon with a target INR of 2 to 3. If INR was &lt;2, bridging with low-molecular-weight heparin was performed.</s></p><p><s>Results: Forty-seven of 200 patients (23.5%) were treated with a vitamin K antagonist (VKA) and 55 (27.5%) were treated with apixaban, 67 (33.5%) with rivaroxaban, and 31 (15.5%) with dabigatran.</s><s>Seven (3.5%) major complications occurred in the overall population.</s><s>Major bleeding complications did not differ significantly between the 2 groups (P = 0.23).</s><s>One patient taking VKA had a pericardial tamponade at the end of the procedure; 2 patients treated with apixaban developed a groin hematoma requiring surgical intervention.</s><s>Transient ischemic attack occurred in 1 patient of the apixaban and rivaroxaban group.</s></p><p><s>Conclusions: Apixaban, rivaroxaban, and dabigatran, compared with uninterrupted VKA, did not show a higher risk for major bleeding or ischemic complications in patients undergoing PVI using the second-generation CB.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">| INTRODUCTION</head><p><s>Pulmonary vein isolation (PVI) using cryoballoon (CB) technology is an established treatment option in symptomatic patients with drugrefractory atrial fibrillation (AF). <ref type="bibr" target="#b0">1</ref> Oral anticoagulation (OAC) is the most important medication for the treatment of AF patients, as it reduces mortality. <ref type="bibr" target="#b1">2</ref></s><s>rge randomized controlled studies have shown efficacy and safety of novel oral anticoagulants (NOACs) in patients with nonvalvular AF, and the current guidelines propose NOACs as a suitable alternative to vitamin K antagonists (VKAs). <ref type="bibr" target="#b2">3</ref></s><s>VKAs have several limitations, including a narrow therapeutic range, therefore requiring frequent monitoring and dose adjustment. <ref type="bibr" target="#b3">4</ref></s><s> patients undergoing PVI, optimal periprocedural management of OAC is essential due to the prothrombotic nature of lesions in the left atrium (LA).</s><s>On the other hand, periprocedural bleeding complications need to be minimized.</s><s>6]<ref type="bibr" target="#b6">[7]</ref> Furthermore, the management of periprocedural anticoagulation varies widely in the currently available studies.</s><s>Most important, although data on the use of NOACs exist, experience, in particular with apixaban, is scarce.</s></p><p><s>The aim of this study was to evaluate the incidence of acute periprocedural complications in a large patient population undergoing PVI using the 28-mm CB while treated with apixaban, rivaroxaban, and dabigatran as compared with VKA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">| METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">| Study population</head><p><s>Two hundred consecutive patients who underwent PVI using the second-generation 28-mm CB (Arctic Front Advance; Medtronic, Inc., Minneapolis, MN) at our institution were evaluated in this retrospective analysis.</s></p><p><s>Demographic and clinical characteristics, including CHA 2 DS 2 -VASc and HAS-BLED scores, concomitant medications, and laboratory results were collected via the electronic medical record during the hospital stay at the time of PVI.</s></p><p><s>This study conforms to the guiding principles of the Declaration of Helsinki of 2014 and was approved by the local ethics committee (EA4/063/15).</s><s>All authors had full access to the data and have read and agreed to the manuscript as written.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">| Anticoagulation management</head><p><s>Patients taking phenprocoumon were recommended to continue their medication with a target international normalized ratio (INR) of between 2.0 and 2.5.</s><s>In case the INR was &lt;2, bridging with lowmolecular-weight heparin (LMWH) was performed.</s></p><p><s>In patients treated with NOACs, the medication was stopped the day of the procedure.</s><s>After transseptal puncture, unfractionated heparin was administered according to body weight, aiming for a target activated clotting time (ACT) &gt;300 s.</s><s>ACT levels were analyzed every 20 min.</s><s>Protamine sulfate was not used routinely at the end of the procedure.</s></p><p><s>NOACs were restarted the evening of the ablation with a reduced dosage regimen, and patients treated with phenprocoumon preprocedurally were continued on phenprocoumon after the ablation.</s><s>Oral anticoagulation (OAC) was recommended for ≥3 months postprocedure and according to the CHA 2 DS 2 -VASc score thereafter.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">| Complications</head><p><s>Major and minor complications were defined according to the Heart Rhythm Society (HRS)/ European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Expert Consensus Statement. <ref type="bibr" target="#b7">8</ref></s><s> brief, major complications were defined as death, atrioesophageal fistula, and permanent injuries such as persisting phrenic nerve palsy or thromboembolic events, including stroke or transient ischemic attack.</s><s>Furthermore, complications requiring surgical intervention, pericardial drainage, or blood transfusion, or resulting in prolonged hospital stay, were considered major complications.</s></p><p><s>Minor complications were defined as hematoma not requiring intervention or mild pericardial effusion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">| PVI procedure</head><p><s>All patients underwent transesophageal echocardiography prior the procedure.</s><s>PVI was performed under deep sedation with propofol and fentanyl.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">| CB ablation</head><p><s>CB ablation was performed as described previously. <ref type="bibr" target="#b8">9</ref></s><s>After a diagnostic catheter was placed in the coronary sinus, LA access was obtained with a single transseptal puncture using a modified Brockenbrough technique under fluoroscopic guidance.</s><s>The 15-Fr steerable sheath (FlexCath Advance; Medtronic) was introduced using the Seldinger technique over a guidewire.</s><s>In those patients who remained in AF after all pulmonary veins were isolated using CB ablation, electrical cardioversion was performed and PVI was reconfirmed during sinus rhythm.</s><s>During cryoablation of the septal pulmonary veins, continuous phrenic nerve stimulation with a decapolar catheter positioned in the superior vena cava was performed.</s><s>Phrenic nerve integrity was monitored by intermittent fluoroscopy and by tactile feedback.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6">| Postprocedural management</head><p><s>Continuous electrocardiographic telemetric monitoring was performed for ≥24 h after the ablation procedure.</s><s>Pericardial effusion was ruled out by transthoracic echocardiography on the day of the procedure.</s><s>Patients were discharged 2 days after the procedure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7">| Statistical analysis</head><p><s>Continuous variables are expressed as mean AE SD; categorical variables are expressed as numbers or percentages.</s><s>For post hoc variant analysis, the Scheffe test was used.</s><s>For percentage frequency, the Pearson χ 2 test was used.</s><s>A P value &lt;0.05 was considered statistically significant.</s><s>Statistical analysis was performed using SPSS Statistics, version 23 (IBM Corp., Armonk, NY).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">| RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">| Baseline characteristics</head><p><s>The study population consisted of 200 patients (83 [41.5%] female, 99 [49.5%] with paroxysmal AF).</s><s>Forty-seven of the 200 (23.5%)</s><s>patients were treated with VKA (group 1) and the remaining 153 (76.5%) patients were treated with NOACs (group 2).</s><s>In the NOAC group, 55 (35.9%) patients were treated with apixaban, 67 (43.8%) with rivaroxaban, and 31 (20.3%) with dabigatran.</s><s>The mean age of patients in group 1 was significantly higher as compared with patients in group 2 (67.5 AE 8.9 years vs 63.3 AE 0.9 years, respectively; P = 0.02).</s><s>Patients in the VKA group were particularly older than patients of the rivaroxaban group (67.5 AE 8.9* years vs 61.90 AE 10.7 years, respectively; Table <ref type="table" target="#tab_0">1</ref>).</s><s>Further baseline characteristics are described in Table <ref type="table" target="#tab_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">| Major complications</head><p><s>Seven major complications (3.5%) were documented in the overall population.</s><s>Two cerebral ischemic events, namely transient ischemic attack, occurred in the apixaban group (5 mg twice daily, no antiplatelet therapy, INR 1.05, partial thromboplastin time [pTT] 31 s) and rivaroxaban group (20 mg, no antiplatelet therapy, INR 1.72, pTT 48 s).</s><s>A further major complication of persistent phrenic nerve palsy was seen in the dabigatran group.</s><s>One pseudoaneurysm with prolonged hospital stay not requiring surgical intervention was documented in the VKA group.</s><s>This patient had no further antiplatelet therapy.</s><s>The INR was 1.8 and the pTT was 42 s (Table <ref type="table" target="#tab_1">2</ref>).</s><s>In 3 patients, major bleeding events were documented during or after ablation.</s><s>One patient taking VKA had a pericardial tamponade at the end of the procedure, and 2 patients treated with apixaban developed a groin hematoma requiring surgical intervention.</s><s>The mean maximum intraprocedural ACT in patients with major bleeding events was 379 AE 137 min and did not differ significantly compared with the ACT in patients without bleeding events (328 AE 56 min; P = 0.13).</s><s>The INR on the day of the procedure of the patient with VKA who developed pericardial tamponade was 2.2; the pTT was 36.5 s.</s><s>This patient did not take any antiplatelet therapy.</s><s>The patients who developed groin hematoma requiring surgical intervention did not take any antiplatelet therapy, and the INRs at admission were 2.16 and 1.05 (with pTTs of 49.5 and 31.0 s).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">| Minor complications</head><p><s>Minor bleeding events included 2 groin hematomas not requiring surgical intervention in the VKA group.</s><s>Both patients did not take antiplatelet therapy.</s><s>The INRs were 1.39 and 1.68, and the pTTs were 37.3 and 42.4 s.</s><s>In these patients, bridging with LMWH was performed (Table <ref type="table" target="#tab_1">2</ref>).</s><s>This study assessed the safety and efficacy of NOACs compared with uninterrupted VKA in patients undergoing CB ablation for AF.</s><s>This study showed that the major complication rate between patients treated with apixaban, rivaroxaban, and dabigatran as compared with patients treated with uninterrupted VKA did not differ significantly.</s></p><p><s>Stroke is one of the most feared complications during ablation of AF.</s><s>On the other hand, there are potential intraprocedural risks for bleeding complications specific to CB ablation, such as large sheaths, the transseptal puncture, and manipulation in the LA.</s><s>Therefore, an optimal peri-and intraprocedural anticoagulation management in patients undergoing CB ablation is essential.</s></p><p><s>In this study, the minority of patients were treated with uninterrupted VKA, and the majority of patients were treated with apixaban, rivaroxaban, and dabigatran.</s><s>Patients treated with VKA were significantly older, which is comparable with the results of other studies. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref></s><s>e safety of uninterrupted warfarin for patients undergoing CB ablation has been shown in several previous studies. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref></s><s>4]<ref type="bibr" target="#b14">[15]</ref> Furthermore, most centers still interrupt NOACs prior to intervention. <ref type="bibr" target="#b15">16</ref></s><s>Besides the bleeding risk due to OAC itself, heparin administration during the ablation procedure, although essential, further increases the risk of bleeding events.</s><s>However, as shown previously by the results of a meta-analysis provided by Briceno et al., the risk of bleeding events for both NOACs and VKA is not increased when using peri-interventional heparin administration with target ACT levels &gt;300 s during ablation procedures.</s><s>In fact, these target ACT levels are associated with lower thromboembolic events. <ref type="bibr" target="#b16">17</ref></s><s>9]<ref type="bibr" target="#b19">[20]</ref> Most of these studies evaluated different periprocedural anticoagulation management protocols, but commonly they confirm the safe use of NOACs.</s></p><p><s>The use of NOACs in CB ablation has been selectively analyzed only in a very limited number of studies.</s><s>Koekturk et al. compared patients undergoing CB ablation with uninterrupted VKA vs patients treated with NOACs. <ref type="bibr" target="#b4">5</ref></s><s>Most patients were treated with dabigatran and rivaroxaban, and only a few patients with apixaban.</s><s>Patients discontinued their medication 24 h before the procedure.</s><s>NOACs were continued the day after the procedure, and bridging with LMWH the evening of the procedure was performed.</s><s>Thus, their periprocedural management differs significantly from our clinical standard, where NOACs were continued on the day of the procedure and no bridging with LMWH was performed.</s><s>Furthermore, more patients were treated with apixaban in our cohort.</s><s>In addition, Okishige et al. compared the use of VKA vs NOACs in Japanese patients undergoing AF ablation with the CB. <ref type="bibr" target="#b5">6</ref> The periprocedural anticoagulation management differed from our institutional standard.</s></p><p><s>Patients treated with VKA had to target an INR from 1.5 to 2.5; and whereas apixaban and dabigatran were given the day of the procedure, rivaroxaban and edoxaban were withheld the day prior to the procedure.</s><s>In contrast to Okishige et al., the patients of our study population were more often treated with apixaban.</s><s>They found a significant higher bleeding risk in patients under VKA, which is in contrast to the findings of our study.</s><s>However, these data were collected in Japan and therefore cannot be compared with European or US populations.</s></p><p><s>Snipelisky et al <ref type="bibr" target="#b6">7</ref> analyzed patients undergoing CB ablation who were treated with rivaroxaban and dabigatran compared with patients treated with VKA.</s><s>Bleeding complications were similar for VKA, rivaroxaban, and dabigatran.</s><s>However, this study population did not include any patients with apixaban.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">| Study limitations</head><p><s>The number of patients in this retrospective analysis is limited, and larger patient populations are needed, in particular for patients with apixaban and edoxaban.</s><s>Further, this is a single-center experience and does not reflect multicenter, international data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">| CONCLUSION</head><p><s>In our single-center experience, apixaban, rivaroxaban, and dabigatran compared with uninterrupted VKA appear to have a comparable risk for bleeding or ischemic complications in patients undergoing PVI using the second-generation CB.</s><s>Larger studies are needed to confirm these findings.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1</head><label>1</label><figDesc><div><p><s>Baseline clinical characteristics of patients treated with phenprocoumon as compared with the 3 different NOAC subgroups</s></p></div></figDesc><table><row><cell>Baseline</cell><cell></cell><cell>Apixaban, N = 55 (2.5 mg,</cell><cell>Rivaroxaban, N = 67 (15 mg,</cell><cell>Dabigatran, N = 31 (110 mg,</cell><cell></cell></row><row><cell>characteristics</cell><cell>VKA, N = 47</cell><cell>n = 9; 5 mg, n = 46)</cell><cell>n = 10; 20 mg, n = 57)</cell><cell>n = 10; 150 mg, n = 21)</cell><cell>P Value</cell></row><row><cell>Age, y</cell><cell>67.5 AE 8.9 a</cell><cell>65.2 AE 11.0</cell><cell>61.90 AE 10.7 a</cell><cell>63.0 AE 10.8</cell><cell>0.032</cell></row><row><cell>Female sex</cell><cell>22 (47)</cell><cell>22 (40)</cell><cell>28 (42)</cell><cell>11 (35.5)</cell><cell>0.79</cell></row><row><cell>BMI, kg/m 2</cell><cell>28.9 AE 4.9</cell><cell>28.1 AE 5.8</cell><cell>28.9 AE 5.5</cell><cell>28.1 AE 4.5</cell><cell>0.83</cell></row><row><cell>CHA 2 DS 2 -</cell><cell>3.1 AE 1.2</cell><cell>2.8 AE 1.6</cell><cell>2.5 AE 1.5</cell><cell>2.6 AE 1.7</cell><cell>0.10</cell></row><row><cell>VASc score</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HAS-BLED</cell><cell>2.0 AE 0.8</cell><cell>1.8 AE 1.3</cell><cell>1.8 AE 1.1</cell><cell>1.8 AE 1.2</cell><cell>0.67</cell></row><row><cell>score</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CAD</cell><cell>15 (32)</cell><cell>14 (26)</cell><cell>9 (13)</cell><cell>11 (36)</cell><cell>0.05</cell></row><row><cell>HTN</cell><cell>38</cell><cell>37</cell><cell>47</cell><cell>23</cell><cell>0.45</cell></row><row><cell>DM</cell><cell>7 (15)</cell><cell>9 (16)</cell><cell>6 (9)</cell><cell>2 (7)</cell><cell>0.41</cell></row><row><cell>COPD</cell><cell>4 (9)</cell><cell>2 (4)</cell><cell>2 (4)</cell><cell>4 (13)</cell><cell>0.19</cell></row><row><cell>CKD</cell><cell>5 (11)</cell><cell>2 (4)</cell><cell>2 (3)</cell><cell>4 (13)</cell><cell>0.14</cell></row><row><cell>GFR, mL/min</cell><cell>69.2 AE 3.8</cell><cell>72.3 AE 16.3</cell><cell>76.3 AE 13.8</cell><cell>67.2 AE 5.7</cell><cell>0.05</cell></row><row><cell>INR value</cell><cell>1.8 AE 0.5 a</cell><cell>1.9 AE 0.19 a</cell><cell>1.2 AE 0.25 a</cell><cell>1.1 AE 0.15 a</cell><cell>&lt;0.001</cell></row><row><cell>Prior ischemic</cell><cell>2 (4)</cell><cell>5 (9)</cell><cell>3 (5)</cell><cell>1 (3)</cell><cell>0.58</cell></row><row><cell>stroke</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>LA diameter,</cell><cell>41.5 AE 6.7</cell><cell>43.1 AE 0.1</cell><cell>42.4 AE 5.4</cell><cell>43.1 AE 6.6</cell><cell>0.70</cell></row><row><cell>mm</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>LVEF, %</cell><cell>63.6 AE 7.1</cell><cell>64.0 AE 7.5</cell><cell>65 AE 8.7</cell><cell>61.3 AE 8.3</cell><cell>0.24</cell></row><row><cell>Paroxysmal</cell><cell>18 (9)</cell><cell>32 (16)</cell><cell>34 (17)</cell><cell>15 (7.5)</cell><cell>0.25</cell></row><row><cell>AF</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ASA</cell><cell>2</cell><cell>2</cell><cell>3</cell><cell>3</cell><cell>0.63</cell></row><row><cell>Clopidogrel</cell><cell>2</cell><cell>4</cell><cell>4</cell><cell>5</cell><cell>0.23</cell></row><row><cell>Procedure</cell><cell>148.1 AE 37.6 a</cell><cell>126.6 AE 25.0 a</cell><cell>131.1 AE 28.6</cell><cell>136.8 AE 38.6</cell><cell>0.006</cell></row><row><cell>time, min</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Fluoroscopy</cell><cell>27.7 AE 11.6</cell><cell>23.7 AE 12.5</cell><cell>23.1 AE 9.8</cell><cell>26.6 AE 8.1</cell><cell>0.10</cell></row><row><cell>time, min</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACT minimum</cell><cell>312.0 AE 75.7 a</cell><cell>263.2 AE 33.7 a</cell><cell>265.8 AE 45.3 a</cell><cell>270.5 AE 37.4 a</cell><cell>&lt;0.001</cell></row><row><cell>ACT</cell><cell>380.3 AE 68.2 a</cell><cell>316.4 AE 51.3 a</cell><cell>311.3 AE 40.4 a</cell><cell>316.1 AE 33.6 a</cell><cell>&lt;0.001</cell></row><row><cell>maximum</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>Abbreviations: ACT, activated clotting time; AF, atrial fibrillation; ASA, acetylsalicylic acid (aspirin); BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GFR, glomerular filtration rate; HTN, hypertension; INR, international normalized ratio; LA, left atrial; LVEF, left ventricular ejection fraction; NOAC, novel oral anticoagulant; SD, standard deviation; TIA, transient ischemic attack; VKA, vitamin K antagonist.Data are presented as n (%) or mean AE SD.TSCHOLL ET AL.1097</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 2</head><label>2</label><figDesc><div><p><s>Complication rate</s></p></div></figDesc><table><row><cell>VKA</cell><cell>Apixaban</cell><cell>Rivaroxaban</cell><cell>Dabigatran</cell><cell>P Value</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">TSCHOLL ET AL.</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of interest</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fürnkranz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Chun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2858" to="2865" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Aguilar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="857" to="867" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kirchhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Benussi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kotecha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1609" to="1678" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Olesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sørensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hansen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="187" to="193" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The total incidence of complications and the impact of an anticoagulation regime on adverse events after cryoballoon ablation of atrial fibrillation: a single-center study of 409 patients</title>
		<author>
			<persName><forename type="first">B</forename><surname>Koektuerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Turan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yorgun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Ther</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="144" to="151" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Okishige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Aoyagi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="11" to="15" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Snipelisky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Ray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Interv Card Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="231" to="236" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design</title>
		<author>
			<persName><forename type="first">H</forename><surname>Calkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cappato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="528" to="606" />
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Two years outcome in patients with persistent atrial fibrillation after pulmonary vein isolation using the second-generation 28-mm cryoballoon</title>
		<author>
			<persName><forename type="first">V</forename><surname>Tscholl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lsharaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart Rhythm</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1817" to="1822" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Microbial stress priming: a meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Andrade-Linares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Rillig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Environ Microbiol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1277" to="1288" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sticherling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Birnie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Europace</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1197" to="1214" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Biase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Burkhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Santangeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="2638" to="2644" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The use of dabigatran immediately after atrial fibrillation ablation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Winkle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Mead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="264" to="268" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cappato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Calkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Arrhythm Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="32" to="38" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Sartori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Imbergamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zanon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Appl Thromb Hemost</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="628" to="635" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Apixaban, rivaroxaban, and dabigatran in patients undergoing atrial fibrillation ablation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rillig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Plesman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="147" to="153" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Clinical impact of heparin kinetics during catheter ablation of atrial fibrillation: meta-analysis and meta-regression</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Briceno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Villablanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lupercio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="683" to="693" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lakkireddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Biase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="982" to="988" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cappato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Marchlinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Hohnloser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1805" to="1811" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Vlachos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Efremidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bazoukis</surname></persName>
		</author>
		<idno type="DOI">10.1002/clc.22734</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Cardiol</title>
		<imprint>
			<date type="published" when="2017-05-31">2017 May 31</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
